<a href="https://www.fiercebiotech.com/biotech/biogen-inks-850m-biobucks-deal-tj-china-rights-late-stage-immune-antibody" hreflang="en">Biogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibody</a>
Biogen has signed an $850 million deal with TJ Biopharma to secure exclusive rights to the late-stage immune antibody felzartamab in China, expanding their partnership and development efforts for the drug, which is currently undergoing phase 3 trials for multiple immune-related conditions. The agreement includes an upfront payment of $100 million and potential milestone payments, with Biogen taking charge of manufacturing and commercialization in the region.
Biogen's $850 million deal with TJ Biopharma to secure China rights for the immune antibody felzartamab exemplifies the strategic importance of expanding market reach in China for biotech firms. This partnership not only enhances Biogen's presence in a market with significant patient populations for IgAN and PMN, but also underscores the value of collaboration with local companies to expedite regulatory processes and market entry. For professionals tracking healthtech and biotech investment opportunities, this deal signals the potential for lucrative partnerships and market expansion in Greater China’s growing biotech landscape.